CholelithiasisNCT00984100
Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy
A study testing NOTES Transvaginal Cholecystectomy in people with Cholelithiasis and Biliary Dyskinesia, run by Baystate Medical Center at 1 site in United States.
Trial summary
Natural Orifice Translumenal Endoscopic Surgery (NOTES) describes a new field of investigational surgery which uses the endoscope as the primary operative tool. The insertion sites for the endoscope include natural orifices such as the mouth, anus, vagina, or urethra. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Cholelithiasis, Biliary Dyskinesia
- What is being tested?
- NOTES Transvaginal Cholecystectomy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2009to Jan 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult female (18 years old or over) patients who are able to provide informed consent for this surgical procedure
- Patients scheduled to undergo non-emergent surgical removal of the gallbladder
Who cannot join
- Inability to provide informed consent
- Patients who have a history of prior pelvic surgery (excluding Caesarian sections, tubal ligations, or non-operative pelviscopy)
- Patients who have acute cholecystitis, gallstone pancreatitis, or who have had a percutaneous cholecystotomy tube placed
- Patients with a BMI > 40 kg/m2
- Pregnancy
- Male gender
- History of PID
Trial locations and contacts
1 site in 1 country.
United States1 site
Baystate Medical Center
Springfield, Massachusetts, 01085
About this study
Natural Orifice Translumenal Endoscopic Surgery (NOTES) describes a new field of investigational surgery which uses the endoscope as the primary operative tool. The insertion sites for the endoscope include natural orifices such as the mouth, anus, vagina, or urethra. Multidisciplinary teams of surgeons and gastroenterologists collaborate to develop safe and effective surgical techniques via the natural orifice route in order to avoid surgical incisions. Early studies have focused on transvaginal surgery as the access route to the abdomen as it sidesteps troubling questions about infection and closure of the organ. This study is a pilot study to test the feasibility to NOTES transvaginal cholecystectomy using conventional surgical and endoscopic tools.
Read the detailed description
Introduction: Natural Orifice Translumenal Endoscopic Surgery (NOTES) describes a new field of investigational surgery which uses the endoscope as the primary operative tool. The insertion sites for the endoscope include natural orifices such as the mouth, anus, vagina, or urethra. Multiple animal studies utilizing similar techniques are ongoing at several institutions, including Baystate Medical Center. These multidisciplinary teams consist of surgeons and gastroenterologists who are collaborating to develop safe and effective surgical techniques via the natural orifice route in order to avoid surgical incisions.
The NOTES team at Baystate began animal studies in May, 2006. Multiple procedures, including but not limited to uterine horn resection (simulating appendectomy), cholecystectomy, nephrectomy, splenectomy, distal pancreatectomy, small bowel resection, mediastinal exploration, and sleeve gastrectomy have been completed successfully by the team. This work has led to a separate, IRB-approved protocol to perform NOTES pancreatic pseudocystgastrostomy in human patients. To date, 2 patients have successfully undergone entirely transluminal, endoscopic cystgastrostomy with a third case upcoming. The focus of much of our research (as well as that of many other investigators), is to develop a secure closure method for the stomach. Unfortunately, key scientific questions remain regarding this technique and thus have limited human trials to date. Given this, we have begun to explore other access techniques.
Gynecologists have long considered transvaginal access to the peritoneum as a safe route of entry into the abdomen. Transvaginal hysterectomy and transvaginal tubal ligation have indeed become a regular part of the gynecologic armamentarium. NOTES surgeons have learned from this access approach and have begun to employ it as a safe route into the abdomen. In fact, investigators in New York1,2; San Diego3; Strasbourg, France4; Mallorca, Spain5; Hamburg, Germany6, Milan, Italy7; and Rio de Janeiro8,9 and São Paulo10, Brazil have all announced transvaginal NOTES procedures involving the gallbladder. All of these approaches, to date, have utilized one or more laparoscopic trocars for safety reasons.
Primary Objective: The primary objective of this pilot study is to demonstrate that the Natural Orifice Translumenal Endoscopic Surgery (NOTES) transvaginal cholecystectomy technique is as safe and effective as standard laparoscopic surgical technique for the resection of gallbladder.
Hypothesis: Patients who undergo Natural Orifice Translumenal Endoscopic Surgery for treatment of their gallbladder disease will experience effective treatment with less discomfort and with quicker recovery than standard surgical techniques.
Introduction: The NOTES team (surgeon and gastroenterologist) at Baystate has extensive experience with animal work in developing novel techniques with commercially available products. Despite performing cholecystectomies in porcine models both through a transgastric and transvaginal approach, we have yet to perform a human case. The surgeons on the team have performed well over a thousand laparoscopic cholecystectomies; the gastroenterologist is a recognized advanced therapeutic endoscopist; and the gynecologist is an expert in transvaginal surgery. We believe that our combination of human experience and animal research will lead to safe attempts to perform the procedure described herein.
Methods: There will be a total of 3 patients undergoing this experimental surgical procedure once meeting all entry criteria and subsequent to obtaining informed consent These patients will be recruited from the Baystate ambulatory surgery clinics.. Preoperative laboratory testing, such as blood work (liver function tests, amylase and lipase, a white blood cell count, and a pregnancy test), as well as ultrasound of the liver to document gallbladder disease will be performed as is the standard for patients undergoing surgical removal of the gallbladder. In this procedure, after the induction of general anesthesia and creation of a culdotomy, a sterile endoscope would be inserted into the vagina and then into the abdomen. Following the insertion of the endoscope, a retraction stitch will be passed through the abdominal wall and into the gallbladder to retract the fundus of the gallbladder in a cephalad direction. A 5-mm trocar will be placed in the umbilicus and will serve two functions: one, to allow for a laparoscope in case the view becomes compromised or substandard; and two, to allow a clip applier to be placed in the abdomen for clipping the cystic artery and cystic duct. Dissection of the gallbladder can commence using endoscopic tools and removal of the specimen will be directly through the culdotomy and out through the vagina. Utilizing this technique, as many as three surgical incisions can be avoided.
Postoperatively, the patient will be kept in the hospital overnight. After discharge, follow-up examination will be conducted at 3-5 days (by telephone), 1 week, and 6 weeks following the procedure to determine the success of the procedure. Longer term follow-up will be determined by the patient's overall condition. For at least the first 3 procedures, a laparoscopic camera will be available on the sterile field and at least one laparoscopic trocar will be employed. As with any operation, we would revert to the next least invasive modality should patient safety and/or degree of difficulty dictate that it be so. In this case, should we encounter difficulties during transvaginal cholecystectomy, we would have a low threshold to revert to laparoscopic cholecystectomy or even to open cholecystectomy as needed.
Safety Monitoring: Due to the novelty of the procedure, safety information will be monitored on a continuous basis. Complications that deviate from expected outcomes from standard laparoscopic cholecystectomy would result in, the study being terminated prematurely or temporarily suspended while we assess the events. A member of the general surgery department will be appointed as a safety monitor and will review all the cases and report to the IRB after the first and third case.
Risks and Benefits: The anticipated risks associated with this type of surgery include:
Bleeding, infection, need for open surgery, bile leak, bile duct injury, and bowel injury. Risks specific to the transvaginal NOTES approach include infection of the vagina, dyspareunia. A vaginal incision has no known adverse effects on either fertility or subsequent childbirth, even within a few weeks of the procedure. The anticipated benefits include a decrease in the amount of pain experienced with laparoscopic cholecystectomy, as well as a more cosmetically acceptable result.
Statistics: As this is a purely descriptive study of feasibility of a new technique, there are no specific statistics to be monitored.
Data Storage: The identifiable data collected will be kept in a locked filing cabinet in the primary investigator's office. Only the PI will have access to this file.
It is anticipated that there will be more similar "natural orifice-type" surgeries in the future for a variety of procedures and a multitude of reasons (no incision, less pain, and less time in the hospital). These surgeries will be some of the first transvaginal cholecystectomies performed in the world.
- Conditions
- Cholelithiasis, Biliary Dyskinesia
- Being tested
- NOTES Transvaginal Cholecystectomy
- Keywords
- Cholelithiasis, Biliary dyskinesia
- Medical subject headings
- Cholelithiasis, Biliary Dyskinesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NOTES Transvaginal CholecystectomyProcedure or surgery
An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
| Study group | Role | What they receive |
|---|---|---|
| Notes Transvaginal Cholecystectomy | Experimental | Patients who undergo a NOTES Transvaginal cholescystectomy. Receives: Procedure: NOTES Transvaginal Cholecystectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Morbidity
Measured: One year
Secondary outcomes (2)
Mortality
Measured: One year
Postoperative pain
Measured: One year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2009 (estimated)
- Study startJan 2009
- Primary completionJan 2015
- Study completionJan 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CholelithiasisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- Baystate Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, John Romanelli, Baystate Medical Center
- Investigators
- John Romanelli, MD, Principal investigator, Baystate Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00984100
- Sponsor's protocol ID
- 08-086
- Status last verified
- Nov 2015
- First submitted
- 23 Sep 2009
- Last updated
- 18 Nov 2015
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Natural Orifice Translumenal Endoscopic Surgery (NOTES) Transvaginal Cholecystectomy
- ClinicalTrials.gov ID
- NCT00984100
- Acronym / sponsor ID
- 08-086
- Conditions
- Cholelithiasis, Biliary Dyskinesia
- Keywords
- Cholelithiasis, Biliary dyskinesia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8 participants (actual)
- Lead sponsor
- Baystate Medical CenterUniversity, hospital or other
- Study start
- Jan 2009
- Primary completion
- Jan 2015 (actual)
- Study completion
- Jan 2015 (actual)
- First posted
- 25 Sep 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Natural Orifice Translumenal Endoscopic Surgery (NOTES) describes a new field of investigational surgery which uses the endoscope as the primary operative tool. The insertion sites for the endoscope include natural orifices such as the mouth, anus, vagina, or urethra. Multidisciplinary teams of surgeons and gastroenterologists collaborate to develop safe and effective surgical techniques via the natural orifice route in order to avoid surgical incisions. Early studies have focused on transvaginal surgery as the access route to the abdomen as it sidesteps troubling questions about infection and closure of the organ. This study is a pilot study to test the feasibility to NOTES transvaginal cholecystectomy using conventional surgical and endoscopic tools.
Detailed description
Introduction: Natural Orifice Translumenal Endoscopic Surgery (NOTES) describes a new field of investigational surgery which uses the endoscope as the primary operative tool. The insertion sites for the endoscope include natural orifices such as the mouth, anus, vagina, or urethra. Multiple animal studies utilizing similar techniques are ongoing at several institutions, including Baystate Medical Center. These multidisciplinary teams consist of surgeons and gastroenterologists who are collaborating to develop safe and effective surgical techniques via the natural orifice route in order to avoid surgical incisions.
The NOTES team at Baystate began animal studies in May, 2006. Multiple procedures, including but not limited to uterine horn resection (simulating appendectomy), cholecystectomy, nephrectomy, splenectomy, distal pancreatectomy, small bowel resection, mediastinal exploration, and sleeve gastrectomy have been completed successfully by the team. This work has led to a separate, IRB-approved protocol to perform NOTES pancreatic pseudocystgastrostomy in human patients. To date, 2 patients have successfully undergone entirely transluminal, endoscopic cystgastrostomy with a third case upcoming. The focus of much of our research (as well as that of many other investigators), is to develop a secure closure method for the stomach. Unfortunately, key scientific questions remain regarding this technique and thus have limited human trials to date. Given this, we have begun to explore other access techniques.
Gynecologists have long considered transvaginal access to the peritoneum as a safe route of entry into the abdomen. Transvaginal hysterectomy and transvaginal tubal ligation have indeed become a regular part of the gynecologic armamentarium. NOTES surgeons have learned from this access approach and have begun to employ it as a safe route into the abdomen. In fact, investigators in New York1,2; San Diego3; Strasbourg, France4; Mallorca, Spain5; Hamburg, Germany6, Milan, Italy7; and Rio de Janeiro8,9 and São Paulo10, Brazil have all announced transvaginal NOTES procedures involving the gallbladder. All of these approaches, to date, have utilized one or more laparoscopic trocars for safety reasons.
Primary Objective: The primary objective of this pilot study is to demonstrate that the Natural Orifice Translumenal Endoscopic Surgery (NOTES) transvaginal cholecystectomy technique is as safe and effective as standard laparoscopic surgical technique for the resection of gallbladder.
Hypothesis: Patients who undergo Natural Orifice Translumenal Endoscopic Surgery for treatment of their gallbladder disease will experience effective treatment with less discomfort and with quicker recovery than standard surgical techniques.
Introduction: The NOTES team (surgeon and gastroenterologist) at Baystate has extensive experience with animal work in developing novel techniques with commercially available products. Despite performing cholecystectomies in porcine models both through a transgastric and transvaginal approach, we have yet to perform a human case. The surgeons on the team have performed well over a thousand laparoscopic cholecystectomies; the gastroenterologist is a recognized advanced therapeutic endoscopist; and the gynecologist is an expert in transvaginal surgery. We believe that our combination of human experience and animal research will lead to safe attempts to perform the procedure described herein.
Methods: There will be a total of 3 patients undergoing this experimental surgical procedure once meeting all entry criteria and subsequent to obtaining informed consent These patients will be recruited from the Baystate ambulatory surgery clinics.. Preoperative laboratory testing, such as blood work (liver function tests, amylase and lipase, a white blood cell count, and a pregnancy test), as well as ultrasound of the liver to document gallbladder disease will be performed as is the standard for patients undergoing surgical removal of the gallbladder. In this procedure, after the induction of general anesthesia and creation of a culdotomy, a sterile endoscope would be inserted into the vagina and then into the abdomen. Following the insertion of the endoscope, a retraction stitch will be passed through the abdominal wall and into the gallbladder to retract the fundus of the gallbladder in a cephalad direction. A 5-mm trocar will be placed in the umbilicus and will serve two functions: one, to allow for a laparoscope in case the view becomes compromised or substandard; and two, to allow a clip applier to be placed in the abdomen for clipping the cystic artery and cystic duct. Dissection of the gallbladder can commence using endoscopic tools and removal of the specimen will be directly through the culdotomy and out through the vagina. Utilizing this technique, as many as three surgical incisions can be avoided.
Postoperatively, the patient will be kept in the hospital overnight. After discharge, follow-up examination will be conducted at 3-5 days (by telephone), 1 week, and 6 weeks following the procedure to determine the success of the procedure. Longer term follow-up will be determined by the patient's overall condition. For at least the first 3 procedures, a laparoscopic camera will be available on the sterile field and at least one laparoscopic trocar will be employed. As with any operation, we would revert to the next least invasive modality should patient safety and/or degree of difficulty dictate that it be so. In this case, should we encounter difficulties during transvaginal cholecystectomy, we would have a low threshold to revert to laparoscopic cholecystectomy or even to open cholecystectomy as needed.
Safety Monitoring: Due to the novelty of the procedure, safety information will be monitored on a continuous basis. Complications that deviate from expected outcomes from standard laparoscopic cholecystectomy would result in, the study being terminated prematurely or temporarily suspended while we assess the events. A member of the general surgery department will be appointed as a safety monitor and will review all the cases and report to the IRB after the first and third case.
Risks and Benefits: The anticipated risks associated with this type of surgery include:
Bleeding, infection, need for open surgery, bile leak, bile duct injury, and bowel injury. Risks specific to the transvaginal NOTES approach include infection of the vagina, dyspareunia. A vaginal incision has no known adverse effects on either fertility or subsequent childbirth, even within a few weeks of the procedure. The anticipated benefits include a decrease in the amount of pain experienced with laparoscopic cholecystectomy, as well as a more cosmetically acceptable result.
Statistics: As this is a purely descriptive study of feasibility of a new technique, there are no specific statistics to be monitored.
Data Storage: The identifiable data collected will be kept in a locked filing cabinet in the primary investigator's office. Only the PI will have access to this file.
It is anticipated that there will be more similar "natural orifice-type" surgeries in the future for a variety of procedures and a multitude of reasons (no incision, less pain, and less time in the hospital). These surgeries will be some of the first transvaginal cholecystectomies performed in the world.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Notes Transvaginal Cholecystectomy | Experimental | Procedure: NOTES Transvaginal CholecystectomyPatients who undergo a NOTES Transvaginal cholescystectomy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Adult female (18 years old or over) patients who are able to provide informed consent for this surgical procedure
- Patients scheduled to undergo non-emergent surgical removal of the gallbladder
Key exclusion criteria (7 listed)
- Inability to provide informed consent
- Patients who have a history of prior pelvic surgery (excluding Caesarian sections, tubal ligations, or non-operative pelviscopy)
- Patients who have acute cholecystitis, gallstone pancreatitis, or who have had a percutaneous cholecystotomy tube placed
- Patients with a BMI > 40 kg/m2
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NOTES Transvaginal CholecystectomyAn operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity). | Procedure or surgery | Notes Transvaginal Cholecystectomy |
Primary outcome
Morbidity
Time frame: One year
2 secondary outcomes
Mortality
Time frame: One year
Postoperative pain
Time frame: One year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2015.
Related trials for Cholelithiasis
Not yet recruitingPhase 4
Effect of Prophylactic Dexamethasone vs Placebo on Airway Dimensions Assessed by Ultrasonography in Patients Undergoing Laparoscopic Cholecystectomy
Airway Edema, Postoperative Complications
Not yet recruiting
Two Bupivacaine Concentrations for Recto-Intercostal Fascial Plane Block After Laparoscopic Cholecystectomy
Postoperative Pain, Acute Pain
Active, not recruiting
Comparison of the Efficacy of Different Analgesic Strategies for Pain Control After Laparoscopic Cholecystectomy (LC)
Gallstones, Pain
RecruitingObservational study
Electrosurgical Patterns and Learning Curve in Elective Laparoscopic Cholecystectomy
Cholelithiasis
Recruiting
Timing of CHolecystectomy In Severe PAncreatitis
Acute Pancreatitis, Cholelithiasis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John Romanelli, MD principal investigator
Baystate Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NOTES Transvaginal Cholecystectomy in people with Cholelithiasis and Biliary Dyskinesia, run by Baystate Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Morbidity (time frame: One year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2015.